One event. Multiple sources.
Health

Next-generation drug reduces endometrial cancer progression and death in trial

1 publisher first detected 2% of 46 Health publishers

Headline as filed by Medical Xpress.

Compare coverage — 1 report

Every publisher that filed on this event, earliest first, with each one's headline, summary, times and how long after the first report they filed.
Publisher Headline Summary Published Detected Delay Source Status
Medical Xpress Next-generation drug reduces endometrial cancer progression and death in trial
A new drug is effective at decreasing the recurrence of, and death from, endometrial cancer, an international study shows. The drug, called sacituzumab tirumotecan (sac-TMT), attaches to a protein on
0m medicalxpress.com First

Headlines and summaries belong to the publisher named beside them. “Published” is what their feed stated; “detected” is when PageNews first held the report. Delay is measured from the earliest report on this event and describes timing only.

Reader comments

Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.

Nobody has commented on this story yet.

Add a comment

Up to 2,000 characters. Links are not accepted. Blank lines separate paragraphs.

Related coverage

connected by shared subjects